{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06133972",
            "orgStudyIdInfo": {
                "id": "CVAY736F12301E1"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-505929-14",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Novartis",
                "class": "INDUSTRY"
            },
            "briefTitle": "Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Patients With Lupus (SIRIUS-SLE Extension).",
            "officialTitle": "A Randomized, Double-blind, Placebo-controlled Extension Study to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Lupus (SIRIUS-SLE Extension)",
            "acronym": "SIRIUS-SLE LTE",
            "therapeuticArea": [
                "Immunology and Rheumatology"
            ],
            "study": "phase-extension-study-to-evaluate-long-term-safety-of-ianalumab-in-patients-with-lupus-sirius-sle-extension"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-21",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2029-12-25",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2031-12-23",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-10-02",
            "studyFirstSubmitQcDate": "2023-11-15",
            "studyFirstPostDateStruct": {
                "date": "2023-11-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Novartis Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to assess long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).",
            "detailedDescription": "The purpose of this extension study is to assess long-term safety and tolerability of ianalumab administered s.c. monthly or quarterly, compared to monthly placebo, in adolescent and adult patients with anti-nuclear antibody (ANA)-positive systemic lupus erythematosus of moderate-to-severe disease activity, who have completed either CVAY736F12301 (SIRIUS-SLE 1) or CVAY736F12302 (SIRIUS-SLE 2) core studies."
        },
        "conditionsModule": {
            "conditions": [
                "Systemic Lupus Erythematosus"
            ],
            "keywords": [
                "Systemic Lupus Erythematosus",
                "SLE",
                "B cell depletion",
                "SLEDAI-2K",
                "BILAG-2004",
                "SRI-4, ANA",
                "ianalumab",
                "VAY736"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "The trial is designed to evaluate long-term safety, tolerability and efficacy of two regimen of ianalumab versus placebo, given as monthly or quarterly subcutaneous (s.c.) injection",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 550,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Ianalumab monthly",
                    "type": "EXPERIMENTAL",
                    "description": "Ianalumab s.c. monthly",
                    "interventionNames": [
                        "Drug: Ianalumab"
                    ]
                },
                {
                    "label": "Ianalumab quarterly",
                    "type": "EXPERIMENTAL",
                    "description": "Ianalumab s.c. quarterly",
                    "interventionNames": [
                        "Drug: Ianalumab"
                    ]
                },
                {
                    "label": "Placebo monthly",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo s.c. monthly",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo s.c. monthly",
                    "armGroupLabels": [
                        "Placebo monthly"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Ianalumab",
                    "description": "Ianalumab s.c. monthly Ianalumab s.c. quarterly",
                    "armGroupLabels": [
                        "Ianalumab monthly",
                        "Ianalumab quarterly"
                    ],
                    "otherNames": [
                        "VAY736"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of treatment-emergent Adverse events/Serious Adverse events",
                    "description": "Assessment of long-term safety and tolerability of ianalumab",
                    "timeFrame": "through study completion, up to approximately 91 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Proportion of participants who achieved Systemic Lupus Erythematosus Responder Index -4 (SRI-4) response",
                    "description": "SRI-4 response is defined as:\n\n* Systemic Lupus Erythematosus Disease Activity Index - 2000 (SLEDAI-2K) reduction from baseline of \u2265 4 points\n* No British Isles Lupus Assessment Group-2004 (BILAG-2004) worsening, defined as \u2265 1 new A or \u2265 2 new B items compared to baseline\n* No worsening in Physician Global Assessment of Disease Activity (PhGA), defined as an increase of \u2265 0.3 from baseline on a 0 to 3 visual analog scale",
                    "timeFrame": "up to Week 216"
                },
                {
                    "measure": "Change in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index",
                    "description": "SLICC/ACR Damage Index is a measure of cumulative damage due to SLE",
                    "timeFrame": "up to Week 216"
                },
                {
                    "measure": "Average daily dose of oral corticosteroids administered",
                    "description": "Evaluating the effect of ianalumab on corticosteroids intake",
                    "timeFrame": "up to Week 216"
                },
                {
                    "measure": "Annualized BILAG moderate or severe flare rate",
                    "description": "Annualized BILAG moderate or severe flare rate where moderate BILAG flare is defined as 2 or more new BILAG-2004 B items, and severe BILAG flare is defined as 1 or more new BILAG-2004 A items, compared to the previous visit",
                    "timeFrame": "up to Week 216"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Signed informed consent prior to participation in the extension study. Parent or legal guardian's signed informed consent and child's assent, if appropriate, are required before any assessment is performed for participants \\<18 years of age. Of note, if the participant reaches age of consent (age as per local law) during the study, they will also need to sign the corresponding study Informed Consent Form (ICF) at the next study visit.\n* Participants must have participated in either one of the two SIRIUS-SLE core studies, CVAY736F12301 or CVAY736F12302, and have completed the treatment period through Week 60 without treatment discontinuation.\n* In the judgement of the investigator, participants must be expected to clinically benefit from continued study treatment.\n\nKey Exclusion Criteria:\n\n* Use of prohibited therapies.\n* Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for clinically significant infection which in the opinion of the investigator will place the participant at risk for participation.\n* Plans for administration of live vaccines during the study period.\n* Pregnant or nursing (lactating) women.\n* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, refusing or unable to use highly effective methods of contraception while on study treatment and for 6 months after stopping of study drug (or longer if required by concomitant medications).\n* United States (and other countries, if locally required): sexually active males, unless they agree to use barrier protection during intercourse with women of child-bearing potential while taking study treatment.\n\nOther protocol-defined inclusion/exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "12 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Novartis Pharmaceuticals",
                    "role": "CONTACT",
                    "phone": "1-888-669-6682",
                    "email": "novartis.email@novartis.com"
                },
                {
                    "name": "Novartis Pharmaceuticals",
                    "role": "CONTACT",
                    "phone": "+41613241111",
                    "email": "novartis.email@novartis.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Novartis Pharmaceuticals",
                    "affiliation": "Novartis Pharmaceuticals",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Clinical Res Of W Florida",
                    "status": "RECRUITING",
                    "city": "Clearwater",
                    "state": "Florida",
                    "zip": "33765",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Cheyanne Morales",
                            "role": "CONTACT",
                            "phone": "727-466-0078",
                            "email": "cmorales@crwf.com"
                        },
                        {
                            "name": "Robert Levin",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.96585,
                        "lon": -82.8001
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "RECRUITING",
                    "city": "Maroochydore",
                    "state": "Queensland",
                    "zip": "4558",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -26.66008,
                        "lon": 153.09953
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "RECRUITING",
                    "city": "Rimouski",
                    "state": "Quebec",
                    "zip": "G5L 5T1",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 48.44879,
                        "lon": -68.52396
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "state": "Catalunya",
                    "zip": "08035",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "RECRUITING",
                    "city": "Santiago De Compostela",
                    "state": "Galicia",
                    "zip": "15706",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 42.88052,
                        "lon": -8.54569
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.\n\nThis trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008180",
                    "term": "Lupus Erythematosus, Systemic"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003240",
                    "term": "Connective Tissue Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11177",
                    "name": "Lupus Erythematosus, Systemic",
                    "asFound": "Systemic Lupus Erythematosus",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6464",
                    "name": "Connective Tissue Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}